Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

被引:177
作者
Coustan-Smith, E
Sancho, J
Behm, FG
Hancock, ML
Razzouk, BI
Ribeiro, RC
Rivera, GK
Rubnitz, JE
Sandlund, JT
Pui, CH
Campana, D
机构
[1] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA
[3] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA
[4] Univ Tennessee, Memphis, TN USA
关键词
D O I
10.1182/blood-2002-01-0006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Early clearance of leukemic cells is a favorable prognostic indicator in childhood acute lymphoblastic leukemia (ALL). However, identification of residual leukemic cells by their morphologic features is subjective and lacks sensitivity. To improve estimates of leukemia clearance, we applied flow cytometric techniques capable of detecting 1 leukemic cell in 10 000 or more normal cells and prospectively measured residual leukemia in bone marrow samples collected on day 19 of remission-induction chemotherapy from 248 children with newly diagnosed ALL. In 134 samples (54.0%), we identified at least 0.01% leukemic cells (0.01%-<0.1% in 51 samples [20.6%], 0.1%-<1% in 36 [14.5%], and greater than or equal to1% in 47 [19.0%]). Among 110 children treated within a single chemotherapy program, the 5-year mean +/- SE cumulative incidence of relapse or failure to achieve remission was 32.2%+/-6.5% for the 59 patients with 0.01% residual leukemic cells or greater on day 19 and 6.0%+/-3.4% for the 51 patients with less than 0.01% leukemic cells (P<.001). The prognostic value of day-19 bone marrow status defined by flow cytometry was superior to that defined by morphologic studies and remained significant after adjustment for other clinical and biologic variables. Lack of detectable leukemic cells on day 19 was more closely associated with relapse-free survival than was lack of detectable residual disease at the end of remission induction (day 46). Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome.
引用
收藏
页码:52 / 58
页数:7
相关论文
共 36 条
  • [1] Immunophenotyping of leukemia
    Campana, D
    Behm, FG
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 243 (1-2) : 59 - 75
  • [2] Campana D, 1999, CYTOMETRY, V38, P139, DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO
  • [3] 2-H
  • [4] DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE
    CAMPANA, D
    PUI, CH
    [J]. BLOOD, 1995, 85 (06) : 1416 - 1434
  • [5] Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia
    Chen, JS
    Coustan-Smith, E
    Suzuki, T
    Neale, GA
    Mihara, K
    Pui, CH
    Campana, D
    [J]. BLOOD, 2001, 97 (07) : 2115 - 2120
  • [6] Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
    Coustan-Smith, E
    Sancho, J
    Hancock, ML
    Boyett, JM
    Behm, FG
    Raimondi, SC
    Sandlund, JT
    Rivera, GK
    Rubnitz, JE
    Ribeiro, RC
    Pui, CH
    Campana, D
    [J]. BLOOD, 2000, 96 (08) : 2691 - 2696
  • [7] Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
    Coustan-Smith, E
    Behm, FG
    Sanchez, J
    Boyett, JM
    Hancock, ML
    Raimondi, SC
    Rubnitz, JE
    Rivera, GK
    Sandlund, JT
    Pui, CH
    Campana, D
    [J]. LANCET, 1998, 351 (9102) : 550 - 554
  • [8] Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
    Dördelmann, M
    Reiter, A
    Borkhardt, A
    Ludwig, WD
    Götz, N
    Viehmann, S
    Gadner, H
    Riehm, H
    Schrappe, M
    [J]. BLOOD, 1999, 94 (04) : 1209 - 1217
  • [9] Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
    Evans, WE
    Relling, MV
    Rodman, JH
    Crom, WR
    Boyett, JM
    Pui, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (08) : 499 - 505
  • [10] Pharmacogenomics: Translating functional genomics into rational therapeutics
    Evans, WE
    Relling, MV
    [J]. SCIENCE, 1999, 286 (5439) : 487 - 491